<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328064</url>
  </required_header>
  <id_info>
    <org_study_id>alexmed116619312</org_study_id>
    <nct_id>NCT04328064</nct_id>
  </id_info>
  <brief_title>The Role of Rosuvastatin on Vascular Involvement in Behçet's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Behçet's Disease(BD) is a systemic inflammatory vasculitis, which affects all types and sizes
      of vessels. Statins display numerous effects often independent of the well-established
      lipid-lowering effects that may be of benefit in retarding or preventing vascular injury and
      ischaemic vascular events. The aim of the present study was to determine the efficacy of
      rosuvastatin in improving vascular dysfunction and vascular inflammation and to assess the
      effect of rosuvastatin on vascular involvement in BD patients. Fifty-six BD patients (51
      males and 5 females) mean age 33.4 years, mean disease duration 5.8 years), all fulfilling
      the classification criteria of the International Study Group for Behçet's disease were
      recruited.Patients were randomised into 2 groups.

      The first group (n=27: 20 active and 7 inactive) were assigned to receive 40 mg of
      rosuvastatin and the second group(n=29: 21 active and 8 inactive) received placebo for 12
      months. Inflammatory and endothelial dysregulation markers were measured at baseline and
      after 12 months. All patients were examined for vascular involvement. Venous or arterial
      system involvement was defined as present when confirmed by Doppler ultrasonography, magnetic
      resonance angiography, conventional angiography or CT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in endothelial and vascular inflammatory markers</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome measures included alterations in endothelial injury and vascular inflammatory markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new-onset vascular involvement</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Behcet's Disease</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug-rosuvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin calcium 40mg</intervention_name>
    <description>Active drug -Rosuvastatin</description>
    <arm_group_label>Placebo drug</arm_group_label>
    <arm_group_label>Rosuvastatin Drug</arm_group_label>
    <other_name>Experimental active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>40 mg placebo for 12 months</description>
    <arm_group_label>Placebo drug</arm_group_label>
    <arm_group_label>Rosuvastatin Drug</arm_group_label>
    <other_name>Placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients fulfilling the classification criteria of the International Study Group
             for Behçet's disease

        Exclusion Criteria:

          -  smoking,

          -  diabetes mellitus,

          -  hypercholesterolaemia,

          -  hypertension,

          -  cardiac insufficiency,

          -  coexisting hepatic and renal diseases

          -  inflammatory diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Anna Abou-Raya</investigator_full_name>
    <investigator_title>Professor of Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Behcet's Disease</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Vascular Markers</keyword>
  <keyword>Improvement in vascular involvement in Behcet's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

